Myometrial effects of selective estrogen receptor modulators on estradiol-responsive gene expression are gene and cell-specific.
We examined in vivo effects of selective estrogen receptor modulators (SERMs) 4-OH-tamoxifen (Tam), GW 5638 (GW) and EM-800 (EM) on myometrial gene expression. The uteri of ovariectomized ewes were infused with 10(-7)M of one SERM via indwelling catheters for 24h preceding hysterectomy. Half of the ewes in each SERM group received an intramuscular injection of 50 microg 17beta-estradiol (E2) 18 h prior to hysterectomy. Northern blot analysis and in situ hybridization demonstrated that E2 increased estrogen receptor (ER), progesterone receptor (PR) and cyclophilin (CYC) gene expression in the cells of both inner layer of myometrium (IM) and outer layer of myometrium (OM) as well as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression in OM. Tam also increased ER mRNA levels in OM. EM appeared to increase ER gene expression, but antagonized E2's up-regulation of PR and CYC gene expression in both IM and OM. Tam and GW also antagonized E2 up-regulation of PR gene expression in OM but not IM. No SERM affected GAPDH gene expression with or without E2. Immunohistochemistry indicated that E2 increased nuclear ER and PR protein levels in both IM and OM. EM was unique in up-regulating ER protein levels, opposite to its effects in endometrial cells. All SERMs tested antagonized this increase in PR immunostaining preferentially in OM compared to the IM layer. These results illustrate gene and cell layer-specific effects of SERMs in sheep myometrium.
Farnell
Yuhua Z
YZ
Department of Animal Science, Faculties of Genetics and Reproductive Biology, Texas A&M University, College Station, TX 77843-2471, USA.
Ing
Nancy H
NH
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology; D015152:Blotting, Northern; D002934:Cinnamates / Q000494:pharmacology; D021983:Cyclophilins / Q000096:biosynthesis; D004958:Estradiol / Q000235:genetics / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000096:biosynthesis; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D009215:Myometrium / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011422:Propionates / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry / Q000494:pharmacology*; D012756:Sheep; D013267:Stilbenes / Q000494:pharmacology; D013629:Tamoxifen / Q000737:chemistry / Q000494:pharmacology
D001578:Benzopyrans; D002934:Cinnamates; D011422:Propionates; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D020845:Selective Estrogen Receptor Modulators; D013267:Stilbenes; D013629:Tamoxifen; C087550:3-(4-(1,2-diphenylbut-1-enyl)phenyl)acrylic acid; D004958:Estradiol; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D021983:Cyclophilins; C106945:EM 800